Technology transfer / Localization · Latin America · Announced 21 Oct 2026

Samsung Bioepis → Bionovis

Bionovis is the private Brazilian partner, alongside state lab Bahiafarma, in Samsung Bioepis's 10-year PDP to supply and then locally manufacture the eculizumab biosimilar SB12 for the SUS from 2027.

Parties: Samsung Bioepis (South Korea) → Bionovis (Brazil)

Value
Undisclosed
Territory
Brazil — supply to the public health system (SUS) under a Productive Development Partnership
Therapeutic area
Rare / Orphan
Asset
SB12 (eculizumab)
Announced
21 Oct 2026

Our analysis

Why this matters

Samsung Bioepis announced on 21 October 2026 a 10-year Productive Development Partnership (PDP) to supply SB12, its eculizumab biosimilar, to Brazil's public health system (SUS) from 2027. Bionovis, a local pharmaceutical company, is one of two Brazilian partners; the other is the state laboratory Bahiafarma (listed separately). Manufacturing moves gradually from Samsung Bioepis to the partners. No value was disclosed.

Brazilian public spending on eculizumab exceeded BRL 947 million (about US$171 million) in 2025, according to IQVIA data cited by the company.

The full analysis is free to read with a work email on this page.

Source: BioSpectrum Asia

More deals involving Samsung Bioepis or Bionovis

Latest deals

All Latin America deals → · All technology transfer / localization deals → · Browse all emerging-market pharma deals →